## Cardiovascular System: Key Conditions & Management

The cardiovascular system is vital, and its disorders are a major cause of morbidity and mortality. Pharmacists play a crucial role in optimising treatment and providing patient counselling.

Hypertension

Hypertension (high blood pressure) is a persistent elevation of arterial blood pressure. Untreated, it increases risk of stroke, heart attack, heart failure, and kidney disease.

• Diagnosis & Targets: Usually diagnosed over several readings. Target BP is generally <140/90 mmHg, or <135/85 mmHg at home.
• First-line treatments:
• <55 years, non-black: ACE inhibitors (e.g., ramipril) or ARBs (e.g., losartan).
• Side effects: Dry cough (ACEi), hyperkalaemia, renal impairment.
• Monitoring: BP, renal function (urea, creatinine), electrolytes (potassium).
• ≥55 years or black, any age: Calcium Channel Blockers (CCBs) (e.g., amlodipine) or Thiazide-like Diuretics (e.g., indapamide).
• CCBs side effects: Ankle oedema, flushing, headache.
• Thiazide-like diuretics side effects: Hypokalaemia, hyponatraemia, photosensitivity, gout exacerbation.
• Monitoring: BP, electrolytes (potassium, sodium).
• Lifestyle: Diet (low salt), exercise, limit alcohol, stop smoking.

Ischaemic Heart Disease (IHD) / Angina

Angina is chest pain due to reduced blood flow to the heart muscle.

• Acute Management: Glyceryl Trinitrate (GTN) spray/tablets sublingually for rapid relief.
• Long-term Prevention:
• Antiplatelets: Aspirin (low dose) or clopidogrel to prevent clot formation.
• Beta-blockers (e.g., bisoprolol): Reduce heart rate and contractility, decreasing oxygen demand.
• Calcium Channel Blockers (e.g., amlodipine, diltiazem): Improve coronary blood flow and reduce cardiac workload.
• Statins (e.g., atorvastatin): Lower cholesterol, stabilise plaques.
• ACE inhibitors: Improve endothelial function and reduce remodelling.

Heart Failure

Heart failure occurs when the heart cannot pump enough blood to meet the body's needs.

• Symptoms: Breathlessness, fatigue, ankle swelling.
• Key Drug Classes (HFrEF):
• ACE inhibitors/ARBs: Reduce afterload and remodelling.
• Beta-blockers: Improve cardiac function and reduce mortality (titrated slowly).
• Mineralocorticoid Receptor Antagonists (MRAs) (e.g., spironolactone, eplerenone): Reduce fluid retention and mortality; risk of hyperkalaemia.
• SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin): Reduce hospitalisations and mortality.
• Loop Diuretics (e.g., furosemide): For symptomatic relief of fluid overload (not mortality benefit).
• Monitoring: Renal function, electrolytes (especially potassium with ACEi/ARBs/MRAs).

Dyslipidaemia

High cholesterol levels increase the risk of atherosclerosis.

• Statins (e.g., atorvastatin, simvastatin): First-line for lowering LDL-C. Inhibit HMG-CoA reductase.
• Side effects: Myopathy (muscle pain/weakness), rhabdomyolysis (rare but serious), elevated LFTs.
• Interactions: CYP3A4 inhibitors (e.g., clarithromycin, amiodarone, grapefruit juice) increase statin levels, increasing risk of myopathy.
• Counselling: Take simvastatin/pravastatin at night; atorvastatin/rosuvastatin can be taken any time. Report unexplained muscle pain.

## The Nervous System: Overview

The nervous system is divided into the Central Nervous System (CNS) (brain and spinal cord) and the Peripheral Nervous System (PNS) (nerves outside the CNS). The PNS further splits into the somatic (voluntary) and autonomic (involuntary) systems. Key neurotransmitters include Acetylcholine (ACh), Noradrenaline (NA), Dopamine (DA), Serotonin (5-HT), Gamma-aminobutyric acid (GABA), and Glutamate, each with specific roles and receptor targets.

## Epilepsy

Epilepsy is a neurological disorder characterised by recurrent, unprovoked seizures due to abnormal electrical activity in the brain. Anti-epileptic drugs (AEDs) work by various mechanisms, including enhancing GABAergic inhibition (e.g., sodium valproate, phenobarbital), blocking voltage-gated sodium channels (e.g., carbamazepine, lamotrigine, phenytoin), or modulating calcium channels (e.g., ethosuximide for absence seizures). Levetiracetam has a unique mechanism involving synaptic vesicle protein 2A (SV2A). Monitoring drug levels is crucial for some AEDs like phenytoin. Sodium valproate is highly teratogenic and requires careful counselling for women of childbearing potential.

## Parkinson's Disease

Parkinson's Disease results from the progressive degeneration of dopaminergic neurons in the substantia nigra, leading to a deficiency of dopamine. Symptoms include tremor, rigidity, bradykinesia (slowness of movement), and postural instability. Treatment aims to increase dopamine levels or mimic its effects:

• Levodopa (combined with carbidopa or benserazide to prevent peripheral metabolism) is the most effective treatment.
• Dopamine agonists (e.g., ropinirole, pramipexole) directly stimulate dopamine receptors.
• MAO-B inhibitors (e.g., selegiline, rasagiline) prevent dopamine breakdown.
• COMT inhibitors (e.g., entacapone) prolong levodopa's effect.

## Neuropathic Pain

Neuropathic pain arises from damage or dysfunction of the nervous system. First-line treatments include tricyclic antidepressants (TCAs) like amitriptyline, SNRIs like duloxetine, and gabapentinoids (gabapentin, pregabalin). These drugs modulate neurotransmission to reduce pain signals. Topical treatments like capsaicin cream or lidocaine patches can be used for localised neuropathic pain.

## Migraine

Migraine is a severe headache often accompanied by nausea, vomiting, and sensitivity to light/sound. Acute treatment involves NSAIDs, paracetamol, or triptans (e.g., sumatriptan, zolmitriptan). Triptans are selective 5-HT1B/1D receptor agonists that cause cranial vasoconstriction and inhibit neuropeptide release. Prophylactic treatments for frequent migraines include beta-blockers (e.g., propranolol), topiramate, or amitriptyline.

## Respiratory System: Key Conditions & Management

The respiratory system is vital for gas exchange, and various conditions can impair its function, significantly impacting quality of life. The GPhC exam often focuses on the management of chronic conditions like asthma and COPD, as well as common infections and their pharmacological interventions.

## Asthma

Asthma is a chronic inflammatory disease of the airways, characterised by reversible airway obstruction, bronchospasm, and hyperresponsiveness. Symptoms include wheezing, breathlessness, chest tightness, and cough, often worse at night or with triggers.

Management principles involve a step-wise approach, aiming for symptom control and prevention of exacerbations.

• Relievers: Short-acting beta2-agonists (SABAs) like salbutamol are used for rapid symptom relief. Over-reliance indicates poor control.
• Preventers: Inhaled corticosteroids (ICS) are the cornerstone of maintenance therapy, reducing airway inflammation. Examples include beclometasone, fluticasone.
• Add-on therapies: Long-acting beta2-agonists (LABAs) (e.g., salmeterol, formoterol) are added to ICS if control is inadequate. Leukotriene receptor antagonists (LTRAs) (e.g., montelukast) can be an alternative or additional therapy.
• Oral corticosteroids (OCS) are reserved for severe exacerbations or very severe chronic asthma.

Patient counselling on correct inhaler technique is paramount for efficacy.

## Chronic Obstructive Pulmonary Disease (COPD)

COPD is a progressive, largely irreversible inflammatory lung disease, primarily caused by long-term exposure to noxious particles or gases, most commonly smoking. It's characterised by persistent respiratory symptoms and airflow limitation. Symptoms include chronic cough, sputum production, and progressive dyspnoea.

Management focuses on symptom relief, reducing exacerbations, and improving exercise tolerance.

• Smoking cessation is the single most effective intervention to slow disease progression.
• Bronchodilators are central to symptomatic relief:
• Short-acting muscarinic antagonists (SAMAs) (e.g., ipratropium) and Long-acting muscarinic antagonists (LAMAs) (e.g., tiotropium, glycopyrronium).
• SABAs and LABAs.
• Patients with frequent exacerbations or features suggestive of asthma-COPD overlap may benefit from ICS in combination with LABA/LAMA.
• Pulmonary rehabilitation and vaccinations (influenza, pneumococcal) are also crucial.

## Respiratory Infections

Common infections include Upper Respiratory Tract Infections (URTIs) like the common cold (viral, self-limiting) and Lower Respiratory Tract Infections (LRTIs) such as bronchitis and pneumonia.

• Antibiotics are only effective against bacterial infections. Most URTIs are viral; antibiotics are generally not indicated.
• For Community-Acquired Pneumonia (CAP), antibiotic choice depends on severity and local resistance patterns (e.g., amoxicillin, doxycycline, macrolides).

## Key Counselling Points

• Inhaler technique: Crucial for all inhaled medications. Demonstrate, observe, and correct.
• Adherence: Emphasise the importance of regular use of preventer medications.
• Smoking cessation: Offer support and appropriate pharmacotherapy (e.g., NRT, varenicline, bupropion).

## Antimicrobial Stewardship & Infections

Antimicrobial Stewardship is crucial to combat antimicrobial resistance (AMR). It ensures optimal antimicrobial use to improve patient outcomes, reduce resistance, and decrease healthcare costs. Key principles include prescribing the right drug, right dose, right route, right duration, and for the right patient (the "5 Rs"). Always consider if an antibiotic is truly necessary, as many infections (e.g., viral URTI) are self-limiting and do not require antibiotics.

## Common Bacterial Infections & Treatments

• Uncomplicated Urinary Tract Infection (UTI):
• First-line: Nitrofurantoin (avoid in GFR <45 mL/min due to lack of efficacy and potential for accumulation) or Trimethoprim (resistance is common; avoid in first trimester of pregnancy due to folate antagonism).
• Duration: Typically 3 days for women, 7 days for men.
• Counsel: Encourage fluid intake.
• Cellulitis:
• First-line: Oral Flucloxacillin. For severe cases or systemic symptoms, IV Benzylpenicillin/Flucloxacillin may be used.
• Duration: Usually 5-7 days.
• Penicillin allergy: Consider Clarithromycin or Doxycycline.
• Community-Acquired Pneumonia (CAP):
• Mild (CURB-65 score 0-1): Oral Amoxicillin.
• Moderate/Severe (CURB-65 score ≥2): Oral or IV Amoxicillin combined with Clarithromycin or Doxycycline.
• Penicillin allergy: Doxycycline or Clarithromycin monotherapy.
• Duration: Typically 5 days for mild-moderate cases.

## Common Fungal Infections & Treatments

• Oral Candidiasis (Thrush):
• First-line: Miconazole oral gel (monitor for drug interactions, especially with warfarin) or Nystatin oral suspension.
• Duration: 7-14 days.
• Vaginal Candidiasis (Thrush):
• First-line: Topical Clotrimazole (cream/pessary) or oral Fluconazole (single dose).
• Counsel: Advise on hygiene, avoiding irritants, and wearing cotton underwear.

## Key Antimicrobial Considerations

• Antimicrobial Resistance (AMR): A significant global health threat. Prudent prescribing and patient education are essential.
• Side Effects:
• Clostridioides difficile (C. diff) infection: Strongly associated with broad-spectrum antibiotics, notably Clindamycin, Cephalosporins, and Fluoroquinolones.
• Photosensitivity: Common with Tetracyclines (e.g., Doxycycline) and Fluoroquinolones.
• QT Prolongation: Risk with Macrolides (e.g., Clarithromycin, Azithromycin) and Fluoroquinolones.
• Tendonitis/Tendon Rupture: A rare but serious adverse effect of Fluoroquinolones, particularly in the elderly or those concurrently using corticosteroids.
• Drug Interactions: Significant interactions include warfarin with Macrolides, Metronidazole, and Fluconazole (increased INR).
• Special Populations:
• Pregnancy: Avoid Tetracyclines (tooth discolouration, bone development issues), Fluoroquinolones (arthropathy concerns), and Trimethoprim (folate antagonist in first trimester). Consult local guidelines.
• Renal Impairment: Dose adjustments are required for many antibiotics (e.g., Aminoglycosides, Penicillins, Cephalosporins) to prevent toxicity.

## The Endocrine System Overview

The endocrine system is a network of glands that produce and secrete hormones directly into the bloodstream. Hormones act as chemical messengers, regulating vital bodily functions including metabolism, growth, reproduction, mood, and fluid balance. Key glands include the pituitary, thyroid, parathyroid, adrenal, pancreas, and gonads.

## Diabetes Mellitus

A chronic metabolic disorder characterised by persistently high blood glucose levels (hyperglycaemia).

• Type 1 Diabetes: An autoimmune condition where the body's immune system destroys the pancreatic beta cells, leading to absolute insulin deficiency. Requires lifelong exogenous insulin administration.
• Type 2 Diabetes: Characterised by insulin resistance (cells don't respond effectively to insulin) and/or a progressive decline in insulin production. Initially managed with lifestyle modifications and oral hypoglycaemics (e.g., metformin as first-line), often progressing to other agents or insulin.
• Monitoring: Regular HbA1c (glycated haemoglobin) for long-term glucose control (target typically <48 mmol/mol), and self-monitoring of blood glucose (SMBG).
• Complications: Acute (Diabetic Ketoacidosis - DKA, Hyperosmolar Hyperglycaemic State - HHS) and chronic (microvascular: retinopathy, nephropathy, neuropathy; macrovascular: cardiovascular disease, stroke).

## Thyroid Disorders

The thyroid gland produces thyroxine (T4) and triiodothyronine (T3), crucial for regulating metabolism, growth, and development.

• Hypothyroidism: An underactive thyroid. Symptoms include fatigue, weight gain, cold intolerance, constipation, dry skin. Treatment is Levothyroxine (synthetic T4), dosed to normalise TSH levels.
• Hyperthyroidism: An overactive thyroid (e.g., Grave's disease). Symptoms include weight loss, heat intolerance, palpitations, anxiety, tremor. Treatment involves antithyroid drugs like Carbimazole or Propylthiouracil (PTU), often with beta-blockers for symptomatic relief.

## Adrenal Gland & Other Hormones

The adrenal glands produce cortisol (stress hormone, metabolism), aldosterone (regulates blood pressure and electrolytes), and sex hormones.

• Addison's Disease: Adrenal insufficiency (low cortisol and aldosterone). Requires lifelong replacement with hydrocortisone (glucocorticoid) and fludrocortisone (mineralocorticoid).
• Parathyroid glands regulate calcium and phosphate levels via Parathyroid Hormone (PTH).
• The pituitary gland is the "master gland," controlling many other endocrine glands.

## Gastro-intestinal System: Key Conditions & Management

The gastro-intestinal (GI) system is vital for digestion and nutrient absorption. Common conditions range from mild, self-limiting issues to chronic inflammatory diseases requiring complex management, often involving lifestyle changes and a variety of pharmacological interventions.

## Gastro-oesophageal Reflux Disease (GORD) & Peptic Ulcer Disease (PUD)

GORD is characterised by reflux of stomach acid into the oesophagus, causing heartburn and regurgitation. Lifestyle modifications (weight loss, avoiding trigger foods, elevating head of bed) are first-line. Pharmacological options include antacids (short-term relief), H2-receptor antagonists (H2RAs) like famotidine (reduce acid production), and Proton Pump Inhibitors (PPIs) like omeprazole/lansoprazole (potently block acid secretion). PPIs are highly effective but should be used at the lowest effective dose for the shortest duration. Counsel patients to take PPIs 30-60 minutes before breakfast. Long-term use may be associated with increased risk of *C. difficile* infection, hypomagnesaemia, and osteoporosis.

PUD involves sores in the stomach or duodenum, often caused by *Helicobacter pylori* (H. pylori) infection or NSAID use. H. pylori eradication typically involves triple therapy: a PPI plus two antibiotics (e.g., amoxicillin and clarithromycin, or metronidazole and clarithromycin) for 7-14 days.

## Inflammatory Bowel Disease (IBD)

IBD encompasses Crohn's disease and Ulcerative Colitis, chronic inflammatory conditions of the GI tract.

• Ulcerative Colitis primarily affects the colon and rectum.
• Crohn's Disease can affect any part of the GI tract from mouth to anus.

Management involves aminosalicylates (5-ASAs) like mesalazine (induce and maintain remission, especially in UC), corticosteroids (e.g., prednisolone, budesonide for acute flares), immunosuppressants (e.g., azathioprine, mercaptopurine, methotrexate – require regular FBC monitoring due to myelosuppression risk), and biologics (e.g., anti-TNF-α agents like infliximab, adalimumab).

## Constipation & Diarrhoea

Constipation is managed with lifestyle changes (fibre, fluids, exercise) and laxatives. Types include: bulk-forming (e.g., ispaghula), osmotic (e.g., lactulose, macrogols), stimulant (e.g., senna, bisacodyl – short-term use only), and stool softeners (e.g., docusate).

Diarrhoea often resolves spontaneously. Loperamide is an opioid-receptor agonist that reduces gut motility, effective for symptomatic relief. Avoid in bloody diarrhoea or high fever due to risk of toxic megacolon.

## Coeliac Disease

An autoimmune condition triggered by gluten, leading to small intestine damage. Management is a strict gluten-free diet. Patients are at increased risk of osteoporosis and require bone density monitoring.

## Malignant Disease and Immunosuppression

Malignant disease (cancer) is characterised by uncontrolled cell growth and the potential to metastasise (spread to other parts of the body). Treatment aims to cure, prolong life, or palliate symptoms.

## Cancer Treatment Modalities

• Chemotherapy: Systemic treatment using cytotoxic drugs that target rapidly dividing cells.
• Mechanisms: Include DNA damage (e.g., platinum compounds, alkylating agents), antimetabolites (e.g., methotrexate, fluorouracil), and microtubule inhibitors (e.g., taxanes, vinca alkaloids).
• Common Side Effects: Myelosuppression (neutropenia, anaemia, thrombocytopenia), nausea and vomiting (N&V), mucositis, alopecia, fatigue, peripheral neuropathy.
• Radiotherapy: Uses ionising radiation to damage cancer cells, primarily for localised disease. Side effects depend on the treated area but commonly include skin reactions, fatigue, and site-specific issues (e.g., dysphagia for head/neck).
• Targeted Therapies: Drugs that specifically interfere with molecules involved in cancer growth and progression, often with better specificity than chemotherapy.
• Examples: Monoclonal antibodies (mAbs) (e.g., trastuzumab for HER2+ breast cancer), tyrosine kinase inhibitors (TKIs) (e.g., imatinib for CML).
• Side Effects: Generally different from chemotherapy, can include rash, diarrhoea, hypertension, cardiac toxicity.
• Immunotherapy: Enhances the body's immune system to recognise and destroy cancer cells.
• Examples: Immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) block proteins that prevent immune cells from attacking cancer.
• Side Effects: Can cause immune-related adverse events (irAEs) affecting any organ (e.g., colitis, pneumonitis, hepatitis, endocrinopathies).
• Hormonal Therapies: Used for hormone-sensitive cancers (e.g., breast, prostate).
• Examples: Tamoxifen (selective oestrogen receptor modulator), aromatase inhibitors (e.g., anastrozole), GnRH analogues (e.g., goserelin).
• Side Effects: Hot flushes, bone density changes, thromboembolism (tamoxifen).
• Surgery: Removal of tumours, often curative for early-stage localised disease.

## Immunosuppression

Immunosuppression is a reduced ability of the immune system to fight infection and disease.

• Causes: Cancer itself, chemotherapy, radiotherapy, corticosteroids, specific immunosuppressants (e.g., ciclosporin, tacrolimus, azathioprine, mycophenolate) used in transplant or autoimmune conditions.
• Consequences: Increased risk of opportunistic infections (bacterial, viral, fungal, protozoal), impaired wound healing, increased risk of secondary malignancies.
• Management:
• Prophylaxis: Prophylactic antibiotics (e.g., co-trimoxazole for PCP), antivirals (e.g., aciclovir for HSV), antifungals (e.g., fluconazole) may be used.
• Monitoring: Regular Full Blood Count (FBC) to monitor for neutropenia, anaemia, thrombocytopenia.
• Patient Education: Crucial for recognising signs of infection (fever, chills), strict hygiene, avoiding sick contacts, vaccination advice.
• Neutropenic Sepsis: A medical emergency requiring urgent broad-spectrum antibiotics.

## Pharmacy Considerations

• Safe Handling: Cytotoxic drugs require specific handling and disposal protocols.
• Side Effect Management: Proactive prescribing and counselling for N&V (antiemetics), neutropenia (G-CSF), mucositis, diarrhoea/constipation.
• Drug Interactions: Many cancer drugs have complex interactions (e.g., CYP450, QT prolongation).
• Adherence & Counselling: Emphasise adherence, managing side effects, infection prevention, and reporting new symptoms.

## Pharmacy Law and Ethics: Core Principles

Pharmacy practice in Great Britain is governed by a robust framework of law and professional ethics, ensuring patient safety and public trust. The General Pharmaceutical Council (GPhC) is the independent regulator for pharmacists, pharmacy technicians, and registered pharmacies.

## GPhC Standards

The GPhC Standards for Pharmacy Professionals outline the behaviour, skills, and knowledge expected of all registrants. Key principles include:

• Person-centred care
• Effective communication
• Professionalism and trust
• Safety and quality
• Leadership and teamwork
• Maintaining fitness to practise

The GPhC Standards for Registered Pharmacies ensure premises and services meet specific requirements for patient safety and effective care.

## Medicines Legislation

• Human Medicines Regulations 2012 (HMR 2012): Governs the manufacture, import, sale, and supply of medicines. It classifies medicines into Prescription Only Medicines (POM), Pharmacy Medicines (P), and General Sales List (GSL). It also dictates labelling requirements, patient information leaflets, and advertising.
• Misuse of Drugs Act 1971 (MDA) & Regulations 2001 (MDR): Controls drugs liable to misuse, classifying them into five Schedules based on their therapeutic usefulness and potential for harm. Schedule 2 and 3 Controlled Drugs (CDs) have specific requirements for prescribing, dispensing, storage, destruction, and record-keeping (e.g., CD registers for S2 CDs).
• Emergency Supply: Pharmacists can supply POMs in emergencies under specific conditions, either at the request of a prescriber or a patient. Strict criteria apply, including assessment of immediate need and record-keeping.

## Confidentiality and Data Protection

Pharmacists have a legal and ethical duty to maintain patient confidentiality. The Data Protection Act 2018 and UK GDPR govern how personal data, including health information, must be processed. This includes principles of lawfulness, fairness, transparency, purpose limitation, data minimisation, accuracy, storage limitation, integrity, confidentiality, and accountability. Valid consent is crucial for sharing patient data, though there are circumstances where information can be shared in the public interest (e.g., safeguarding).

## Responsible Pharmacist (RP)

Every registered pharmacy must have a Responsible Pharmacist on duty when open for business. The RP is legally responsible for the safe and effective running of the pharmacy. They must display their name and GPhC registration number and ensure appropriate records are kept. An RP can be absent from the pharmacy for a maximum of two hours in any 24-hour period, provided specific conditions are met (e.g., pharmacy remains closed for supply of POMs/P medicines).